TAI · 3054.TW
LIWANLI Innovation Co., Ltd.
NT$57.00-NT$0.50 (-0.87%)
LIWANLI Innovation Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.63% below the high.
Loading market information…
TWO · 4172.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 06:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
InnoPharmax Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow InnoPharmax Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan, operates as a specialized pharmaceutical enterprise. The company's core activities revolve around the development and market introduction of therapeutic products, with a particular focus on oncology and various other specialized medical fields within the Taiwanese market. Their current commercial portfolio encompasses N11005, an oral insulin designed for administration with meals, alongside GemOral. They also provide an Imipenem and Cilastatin solution, utilized for treating a broad spectrum of bacterial infections affecting areas such as the lower respiratory tract, skin and soft tissue, internal abdominal organs, gynecological systems, and bone and joints. Furthermore, InnoPharmax offers contrast agents, specifically gadopentetate dimeglumine and gadodiamide; oncology medications like Innomustine and Immurin; and Inpheno tablets, which are indicated for rare diseases. The company also provides advanced technology platforms, including the MUCR system, OralPas, and OralPas Pro. Looking at its research and development pipeline, InnoPharmax has several promising candidates. D07001 is currently in Phase I clinical trials for tumor treatment. C08001 has progressed to Phase III, targeting hypertension, heart failure, and left ventricular dysfunction following a myocardial infarction. Additional compounds in pilot bioequivalence (BE) trials include D07002, a potential supplement for phenylketonuria; C07001 for the management of Parkinson's disease; and N11001, which is being investigated for urological applications. The company is also actively formulating new contrast agents, D0131502 and D0051301.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$57.00-NT$0.50 (-0.87%)
LIWANLI Innovation Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.63% below the high.
NT$23.95-NT$0.10 (-0.42%)
Allied Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 35.01% below the high.
NT$32.30-NT$1.10 (-3.29%)
Chunghwa Chemical Synthesis & Biotech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.82% below the high.
NT$55.70+NT$0.80 (+1.46%)
TSH Biopharm Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 6.07% below the high.
NT$9.42-NT$0.25 (-2.59%)
Sunny Pharmtech Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.54% below the high.
NT$23.00-NT$1.05 (-4.37%)
Advagene Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
NT$27.25-NT$0.55 (-1.98%)
GeneFerm Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.1% below the high.
NT$21.40-NT$0.55 (-2.51%)
Shangya Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 55.69% below the high.
